Regulation of 92-kD gelatinase release in HL-60 leukemia cells [PDF]
, 1994 Matrix metalloproteinase 9 (MMP-9), also known as 92-kD type IV collagenase/gelatinase, is believed to play a critical role in tumor invasion and metastasis. Here, we report that MMP-9 was constitutively released from the human promyelocytic cell line HL-
Petrides, P. E. +2 more
core
Diagnosis and management of neutropenia in adults: Expert guidance
British Journal of Haematology, EarlyView.Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte +5 more
wiley +1 more source
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters [PDF]
, 2009 Imatinib mesylate and nilotinib are highly effective at eradicating the majority of chronic myeloid leukemia (CML) cells; however, neither agent induces apoptosis of primitive CML CD34<sup>+</sup> cells.
Holyoake, T.L. +10 more
core +1 more source
Blocking SETD2 Enhances the Therapeutic Efficiency of Menin Inhibitor in MLL‐Fusion Leukemia
Cancer Science, EarlyView.Combined SETD2 and menin inhibitors make synergistic effects against MLL‐fusion leukemia; the combination therapy reduces the expression of target genes through blocking transcription elongation and initiation. ABSTRACT During transcriptional elongation, the histone methyltransferase SETD2 binds to RNA polymerase II and deposits trimethylation marks at
Anpei Li +10 more
wiley +1 more source
, 2010 Imatinib mesylate is a potent inhibitor of the Bcr-Abl tyrosine kinase, an oncoprotein that plays a key role in the development of chronic myeloid leukemia. Consequently, imatinib is used as front-line therapy for this disease.
Colavita, Irene
core
Proto-oncogene c-jun expression is induced by AML1-ETO in a JNK dependent manner:possible role in the pathogenesis of acute myeloid leukemia [PDF]
, 2003 Overexpression of proto-oncogene c-jun and constitutive activation of the Jun NH2-terminal kinase (JNK) signaling pathway have been implicated in the leukemic transformation process.
Elsaesser, Annika
core
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells [PDF]
, 2011 Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease ...
E K Allan +7 more
core +1 more source
BMC Genomics, 2010 BackgroundChronic myelogenous leukemia (CML) results from the neoplastic transformation of a haematopoietic stem cell. The hallmark genetic abnormality of CML is a chimeric BCR/ABL1 fusion gene resulting from the Philadelphia chromosome rearrangement t(9;
E. Nacheva +9 more
semanticscholar +1 more source
Impact of G‐CSF on Donor TCR Clonal Diversity and T Cell Function During Donor HSC Mobilisation
Cell Proliferation, EarlyView.In this study, we found that G‐CSF mobilisation caused a reduction in TCR clonal diversity and down‐regulation of T‐cell function in donors. This may be one of the reasons for the low incidence of GVHD mediated by G‐CSF after allo‐HSCT. Source: Created in BioRender. Li https://BioRender.com/otownki.
Xinye Li +14 more
wiley +1 more source
Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies
Haematologica, 2007 Chimeric T-cell receptors (ChTCR) are a fascinating technological step in the field of immunotherapy for orienting the activity of immune cells towards specific molecular targets expressed on the cell surface of various tumors, including hematologic ...
Ettore Biagi +5 more
doaj +1 more source